{"name":"sara nabil","slug":"sara-nabil","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"OraVerse Injectable Product","genericName":"OraVerse Injectable Product","slug":"oraverse-injectable-product","indication":"Reversal of soft tissue anesthesia and hemostasis following local anesthetic use in dental procedures","status":"phase_3"}]}],"pipeline":[{"name":"OraVerse Injectable Product","genericName":"OraVerse Injectable Product","slug":"oraverse-injectable-product","phase":"phase_3","mechanism":"OraVerse is a phentolamine mesylate injectable that reverses the effects of local anesthetic vasoconstrictors by blocking alpha-adrenergic receptors.","indications":["Reversal of soft tissue anesthesia and hemostasis following local anesthetic use in dental procedures"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}